Produktname:Ethylthioglycolate

IUPAC Name:ethyl 2-sulfanylacetate

CAS:623-51-8
Molekulare Formel:C4H8O2S
Reinheit:95%+
Katalognummer:CM367508
Molekulargewicht:120.17

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM367508-500g in stock ǎř

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:623-51-8
Molekulare Formel:C4H8O2S
Schmelzpunkt:-
SMILES-Code:CCOC(=O)CS
Dichte:
Katalognummer:CM367508
Molekulargewicht:120.17
Siedepunkt:
Mdl-Nr.:
Lagerung:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Cadisegliatin
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.